Table 3 Mean effective dose received by survivors and controls with proportion of survivors receiving 50 and 100 mSv in years 5 through 15 after diagnosis/referent dates, stratified by malignancy type
Mean Effective Dose, mSv | Survivors Receiving Effective Dose | ||||||
|---|---|---|---|---|---|---|---|
Dose, mSv | n (%) | ||||||
Malignancy Type | n | Survivors | Controls | 50 mSv | 100 mSv | ||
All Malignancies | 20911 | 26.3 | 10.7 | 3333 | (15.9) | 1314 | (6.3) |
Breast | 4581 | 34.4 | 13.0 | 909 | (19.8) | 386 | (8.4) |
Gynecologica | 2782 | 19.6 | 11.2 | 308 | (11.1) | 120 | (4.3) |
Thyroid | 2388 | 18.3 | 10.0 | 258 | (10.8) | 60 | (2.5) |
Melanoma | 2088 | 14.9 | 9.9 | 166 | (8.0) | 60 | (2.9) |
Testicular | 1390 | 23.4 | 7.8 | 241 | (17.3) | 57 | (4.1) |
NHL | 1277 | 46.0 | 10.2 | 364 | (28.5) | 193 | (15.1) |
HL | 1072 | 31.8 | 7.2 | 211 | (19.7) | 98 | (9.1) |
Urologic | 895 | 31.6 | 11.2 | 175 | (19.6) | 76 | (8.5) |
Colorectal | 785 | 26.4 | 12.1 | 140 | (17.8) | 50 | (6.4) |
Head & Neck | 768 | 22.5 | 11.4 | 101 | (13.2) | 40 | (5.2) |
Brain | 632 | 16.3 | 9.4 | 47 | (7.4) | 8 | (1.3) |
Bone & Soft-tissue | 463 | 20.8 | 7.9 | 64 | (13.8) | 24 | (5.2) |
Chest & Lung | 345 | 28.2 | 11.3 | 66 | (19.1) | 29 | (8.4) |
Leukemia | 284 | 26.8 | 8.9 | 55 | (19.4) | 28 | (9.9) |
Upper GI | 274 | 36.7 | 12.0 | 68 | (24.8) | 25 | (9.1) |